Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
AML, Adult Acute Myeloid Leukemia Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute
Lead Scientist at UCSF
- Catherine Smith
My laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML). We have a particular emphasis on AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is mutated in ~30% of AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis.
- accepting new patients
- Start Date
- Completion Date
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Phase 1/2
- Study Type
- Last Updated